Tirzepatide Results Timeline: What Trials Measured

What does the tirzepatide results timeline look like over 72 weeks?

In SURMOUNT-1, group-mean body weight fell steadily across a 72-week period, reaching up to about 22.5 percent at the 15 mg weekly dose (Jastreboff et al., NEJM 2022; doi:10.1056/NEJMoa2206038).

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight who did not have type 2 diabetes. The trial studied three weekly doses, 5 mg, 10 mg, and 15 mg, against placebo, all alongside lifestyle guidance, over 72 weeks that included a 20-week dose-escalation period. The result was dose dependent: higher doses produced larger average reductions.

The trial reported two sets of figures. The efficacy estimand estimates the effect if people stayed on treatment. The treatment-regimen estimand includes everyone as assigned, even those who stopped early, so its numbers are a little smaller. Both are shown below (Jastreboff et al., NEJM 2022).

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Figures are group means from a controlled trial, reported here for education, not as a target or instruction.

When did most of the weight loss happen during the trial?

The reported mean curves fell most steeply in the early months, then kept declining at a slower pace through the rest of the 72 weeks (Jastreboff et al., NEJM 2022; Horn et al., Clinical Obesity 2025).

In trials, tirzepatide is titrated up over several starting weeks rather than begun at full dose, a common approach to manage tolerability. During this early ramp and the months just after, the group-mean weight line dropped fastest. A later analysis of the SURMOUNT trials reported that mean weight reduction in the first 24 weeks was about 13 to 15 percent across groups, with meaningful additional loss between weeks 24 and 72 (Horn et al., Clinical Obesity 2025; doi:10.1111/cob.12734). As the trial went on, the average line kept trending downward but flattened gradually. That shape, quick early change followed by a longer, slower decline, is why a timeline is a curve, not a straight line.

What is a weight-loss plateau, and when does it happen?

A plateau is the point where weight stops falling and holds steady; in the SURMOUNT trials the median time to plateau ranged from about 24 to 36 weeks depending on starting BMI (Horn et al., Clinical Obesity 2025).

Horn et al. (Clinical Obesity 2025) examined how long weight loss continued before it leveled off in SURMOUNT-1 and SURMOUNT-4. Across four BMI categories, the reported median time to weight plateau was about 24.3, 26.0, 36.1, and 36.1 weeks, with higher-BMI groups tending to keep losing longer. The reason a plateau arrives at all is physiology, not failure of the compound. As body weight drops, the body burns fewer calories at rest, a shift called adaptive thermogenesis, while appetite signals push back (Rosenbaum and Leibel, Int J Obes 2010; doi:10.1038/ijo.2010.184). Those forces slow the rate of loss until the timeline flattens.

What happens on the timeline after stopping tirzepatide?

Trial data show substantial weight regain after tirzepatide is stopped, while continued use held the loss (Aronne et al., JAMA 2024).

SURMOUNT-4 used a 36-week open-label lead-in on tirzepatide, then randomized participants either to continue the compound or to switch to placebo for 52 more weeks. From randomization to week 88, the group that continued tirzepatide lost a further mean of about 5.5 percent, while the group switched to placebo regained a mean of about 14.0 percent, a between-group difference of about 19.4 percentage points (Aronne et al., JAMA 2024; doi:10.1001/jama.2023.24945). The same direction of effect appeared with semaglutide: in the STEP 1 trial extension, participants regained about two-thirds of their prior weight loss within a year of stopping (Wilding et al., Diabetes Obes Metab 2022; doi:10.1111/dom.14725). The timeline is not a one-way street; withdrawal reverses part of it.

How does the tirzepatide timeline compare with semaglutide?

In a head-to-head diabetes trial, tirzepatide produced greater weight reduction than semaglutide, and separate obesity trials report larger mean loss for tirzepatide, though the trials are not directly matched (Frias et al., NEJM 2021; Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021).

SURPASS-2 compared tirzepatide against semaglutide 1 mg in 1,879 adults with type 2 diabetes over 40 weeks and found tirzepatide produced greater weight reduction (Frias et al., NEJM 2021; doi:10.1056/NEJMoa2107519). Note the caveats: that was a diabetes trial, the semaglutide dose was the 1 mg diabetes dose rather than the higher obesity dose, and populations differ. Comparing across separate obesity trials, tirzepatide's mean loss (up to about 22.5 percent, Jastreboff et al., NEJM 2022) ran higher than semaglutide's (up to about 15 percent on the treatment-regimen estimand, Wilding et al., NEJM 2021), but cross-trial numbers are not the same as a direct comparison.

Is the tirzepatide timeline a promise of my results?

No; these are reported group averages from controlled trials, and individual response varies widely, so your personal trajectory and any dose belong with a qualified clinician.

A group mean is the average of many people. In the same trial, some participants lost far more than the average and some lost far less. Starting weight, adherence, dose, and the lifestyle support built into each trial all shaped the reported numbers. This page summarizes what the studies measured; it is not a personal forecast, a recommendation, or dosing guidance. Decisions about whether a compound is appropriate, and at what dose, are for a licensed clinician.